CN104207144B - A kind of many polymerizers of high energy type enteral nutrition - Google Patents
A kind of many polymerizers of high energy type enteral nutrition Download PDFInfo
- Publication number
- CN104207144B CN104207144B CN201410503102.5A CN201410503102A CN104207144B CN 104207144 B CN104207144 B CN 104207144B CN 201410503102 A CN201410503102 A CN 201410503102A CN 104207144 B CN104207144 B CN 104207144B
- Authority
- CN
- China
- Prior art keywords
- vitamin
- enteral nutrition
- fatty acid
- fiber
- type enteral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 235000016709 nutrition Nutrition 0.000 title claims abstract description 60
- 230000035764 nutrition Effects 0.000 title claims abstract description 54
- 239000000194 fatty acid Substances 0.000 claims abstract description 23
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 20
- 229930195729 fatty acid Natural products 0.000 claims abstract description 20
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 19
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 12
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 12
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 6
- 239000000843 powder Substances 0.000 claims description 46
- 239000000835 fiber Substances 0.000 claims description 20
- 235000013325 dietary fiber Nutrition 0.000 claims description 19
- 239000003921 oil Substances 0.000 claims description 18
- 235000019198 oils Nutrition 0.000 claims description 18
- -1 compound vitamin Chemical class 0.000 claims description 16
- 102000004407 Lactalbumin Human genes 0.000 claims description 14
- 108090000942 Lactalbumin Proteins 0.000 claims description 14
- 235000019197 fats Nutrition 0.000 claims description 14
- 229920002774 Maltodextrin Polymers 0.000 claims description 11
- 239000005913 Maltodextrin Substances 0.000 claims description 11
- 229940035034 maltodextrin Drugs 0.000 claims description 11
- 235000018102 proteins Nutrition 0.000 claims description 11
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 10
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 10
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 10
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 10
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 229910052711 selenium Inorganic materials 0.000 claims description 10
- 239000011669 selenium Substances 0.000 claims description 10
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 9
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims description 8
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 8
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 8
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 8
- 235000008434 ginseng Nutrition 0.000 claims description 8
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 8
- 239000011707 mineral Substances 0.000 claims description 8
- 210000000582 semen Anatomy 0.000 claims description 8
- 239000011701 zinc Substances 0.000 claims description 8
- 229910052725 zinc Inorganic materials 0.000 claims description 8
- 241001264174 Cordyceps militaris Species 0.000 claims description 7
- 241000195493 Cryptophyta Species 0.000 claims description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 7
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 7
- 108010052008 colla corii asini Proteins 0.000 claims description 7
- 235000021323 fish oil Nutrition 0.000 claims description 7
- 150000004667 medium chain fatty acids Chemical class 0.000 claims description 7
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 claims description 7
- 229910052708 sodium Inorganic materials 0.000 claims description 7
- 239000011734 sodium Substances 0.000 claims description 7
- 229940088594 vitamin Drugs 0.000 claims description 7
- 229930003231 vitamin Natural products 0.000 claims description 7
- 235000013343 vitamin Nutrition 0.000 claims description 7
- 239000011782 vitamin Substances 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 229920001285 xanthan gum Polymers 0.000 claims description 7
- 235000010493 xanthan gum Nutrition 0.000 claims description 7
- 239000000230 xanthan gum Substances 0.000 claims description 7
- 229940082509 xanthan gum Drugs 0.000 claims description 7
- 229920001353 Dextrin Polymers 0.000 claims description 6
- 239000004375 Dextrin Substances 0.000 claims description 6
- 239000002131 composite material Substances 0.000 claims description 6
- 235000019425 dextrin Nutrition 0.000 claims description 6
- 235000008390 olive oil Nutrition 0.000 claims description 6
- 239000004006 olive oil Substances 0.000 claims description 6
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 6
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 5
- 241001061264 Astragalus Species 0.000 claims description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 5
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 5
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 5
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 5
- 229920001202 Inulin Polymers 0.000 claims description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 5
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 5
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 5
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 5
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 5
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 5
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 5
- 229930003779 Vitamin B12 Natural products 0.000 claims description 5
- 229930003471 Vitamin B2 Natural products 0.000 claims description 5
- 229930003316 Vitamin D Natural products 0.000 claims description 5
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 5
- 229930003427 Vitamin E Natural products 0.000 claims description 5
- 229930003448 Vitamin K Natural products 0.000 claims description 5
- 239000005862 Whey Substances 0.000 claims description 5
- 102000007544 Whey Proteins Human genes 0.000 claims description 5
- 108010046377 Whey Proteins Proteins 0.000 claims description 5
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 5
- 235000006533 astragalus Nutrition 0.000 claims description 5
- 235000020958 biotin Nutrition 0.000 claims description 5
- 239000011616 biotin Substances 0.000 claims description 5
- 229960002685 biotin Drugs 0.000 claims description 5
- 239000011575 calcium Substances 0.000 claims description 5
- 229910052791 calcium Inorganic materials 0.000 claims description 5
- 235000014633 carbohydrates Nutrition 0.000 claims description 5
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims description 5
- 239000010949 copper Substances 0.000 claims description 5
- 229910052802 copper Inorganic materials 0.000 claims description 5
- 235000019152 folic acid Nutrition 0.000 claims description 5
- 239000011724 folic acid Substances 0.000 claims description 5
- 229960000304 folic acid Drugs 0.000 claims description 5
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 5
- 150000004676 glycans Chemical class 0.000 claims description 5
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 5
- 229940029339 inulin Drugs 0.000 claims description 5
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 5
- 239000011777 magnesium Substances 0.000 claims description 5
- 229910052749 magnesium Inorganic materials 0.000 claims description 5
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims description 5
- 229940055726 pantothenic acid Drugs 0.000 claims description 5
- 235000019161 pantothenic acid Nutrition 0.000 claims description 5
- 239000011713 pantothenic acid Substances 0.000 claims description 5
- 239000011574 phosphorus Substances 0.000 claims description 5
- 229910052698 phosphorus Inorganic materials 0.000 claims description 5
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims description 5
- 229920001282 polysaccharide Polymers 0.000 claims description 5
- 239000005017 polysaccharide Substances 0.000 claims description 5
- 239000011591 potassium Substances 0.000 claims description 5
- 229910052700 potassium Inorganic materials 0.000 claims description 5
- 229960002477 riboflavin Drugs 0.000 claims description 5
- 210000004233 talus Anatomy 0.000 claims description 5
- 235000019155 vitamin A Nutrition 0.000 claims description 5
- 239000011719 vitamin A Substances 0.000 claims description 5
- 235000019163 vitamin B12 Nutrition 0.000 claims description 5
- 239000011715 vitamin B12 Substances 0.000 claims description 5
- 235000019164 vitamin B2 Nutrition 0.000 claims description 5
- 239000011716 vitamin B2 Substances 0.000 claims description 5
- 235000019166 vitamin D Nutrition 0.000 claims description 5
- 239000011710 vitamin D Substances 0.000 claims description 5
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 5
- 235000019165 vitamin E Nutrition 0.000 claims description 5
- 239000011709 vitamin E Substances 0.000 claims description 5
- 229940046009 vitamin E Drugs 0.000 claims description 5
- 235000019168 vitamin K Nutrition 0.000 claims description 5
- 239000011712 vitamin K Substances 0.000 claims description 5
- 150000003721 vitamin K derivatives Chemical class 0.000 claims description 5
- 229940045997 vitamin a Drugs 0.000 claims description 5
- 229940046008 vitamin d Drugs 0.000 claims description 5
- 229940046010 vitamin k Drugs 0.000 claims description 5
- 229930003451 Vitamin B1 Natural products 0.000 claims description 4
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 4
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 4
- 239000000413 hydrolysate Substances 0.000 claims description 4
- 235000012424 soybean oil Nutrition 0.000 claims description 4
- 239000003549 soybean oil Substances 0.000 claims description 4
- 229960003080 taurine Drugs 0.000 claims description 4
- 229960003495 thiamine Drugs 0.000 claims description 4
- 235000010374 vitamin B1 Nutrition 0.000 claims description 4
- 239000011691 vitamin B1 Substances 0.000 claims description 4
- KWTQSFXGGICVPE-UHFFFAOYSA-N 2-amino-5-(diaminomethylideneamino)pentanoic acid;hydron;chloride Chemical compound Cl.OC(=O)C(N)CCCN=C(N)N KWTQSFXGGICVPE-UHFFFAOYSA-N 0.000 claims description 3
- 244000068988 Glycine max Species 0.000 claims description 3
- 235000010469 Glycine max Nutrition 0.000 claims description 3
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 claims description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 3
- 229930064664 L-arginine Natural products 0.000 claims description 3
- 235000014852 L-arginine Nutrition 0.000 claims description 3
- 235000012343 cottonseed oil Nutrition 0.000 claims description 3
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims description 3
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 3
- 235000019158 vitamin B6 Nutrition 0.000 claims description 3
- 239000011726 vitamin B6 Substances 0.000 claims description 3
- 229940011671 vitamin b6 Drugs 0.000 claims description 3
- 235000016068 Berberis vulgaris Nutrition 0.000 claims description 2
- 241000335053 Beta vulgaris Species 0.000 claims description 2
- 229920000377 Sinistrin Polymers 0.000 claims description 2
- 240000008042 Zea mays Species 0.000 claims description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 235000005822 corn Nutrition 0.000 claims description 2
- 229930182830 galactose Natural products 0.000 claims description 2
- 244000131316 Panax pseudoginseng Species 0.000 claims 1
- 235000009392 Vitis Nutrition 0.000 claims 1
- 241000219095 Vitis Species 0.000 claims 1
- 150000001412 amines Chemical group 0.000 claims 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 claims 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 31
- 201000011510 cancer Diseases 0.000 abstract description 13
- 239000003814 drug Substances 0.000 abstract description 7
- 230000000259 anti-tumor effect Effects 0.000 abstract description 5
- 238000011282 treatment Methods 0.000 abstract description 5
- 230000036039 immunity Effects 0.000 description 16
- 206010061218 Inflammation Diseases 0.000 description 12
- 230000004054 inflammatory process Effects 0.000 description 12
- 150000004668 long chain fatty acids Chemical class 0.000 description 12
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 11
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 10
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- 206010009944 Colon cancer Diseases 0.000 description 8
- 102000000589 Interleukin-1 Human genes 0.000 description 8
- 108010002352 Interleukin-1 Proteins 0.000 description 8
- 108091006374 cAMP receptor proteins Proteins 0.000 description 8
- 239000000839 emulsion Substances 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 239000002994 raw material Substances 0.000 description 8
- 229940091258 selenium supplement Drugs 0.000 description 8
- 241000208340 Araliaceae Species 0.000 description 7
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 7
- 230000002980 postoperative effect Effects 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 6
- 230000033228 biological regulation Effects 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000002757 inflammatory effect Effects 0.000 description 6
- 208000030159 metabolic disease Diseases 0.000 description 6
- 235000010755 mineral Nutrition 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 210000002381 plasma Anatomy 0.000 description 6
- 230000001629 suppression Effects 0.000 description 6
- 102000011632 Caseins Human genes 0.000 description 5
- 108010076119 Caseins Proteins 0.000 description 5
- 102100031051 Cysteine and glycine-rich protein 1 Human genes 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 230000002708 enhancing effect Effects 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 235000008216 herbs Nutrition 0.000 description 5
- 230000010354 integration Effects 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 230000004614 tumor growth Effects 0.000 description 5
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 4
- 208000002720 Malnutrition Diseases 0.000 description 4
- 229930003268 Vitamin C Natural products 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 235000000824 malnutrition Nutrition 0.000 description 4
- 230000001071 malnutrition Effects 0.000 description 4
- 208000015380 nutritional deficiency disease Diseases 0.000 description 4
- 235000003715 nutritional status Nutrition 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 238000001694 spray drying Methods 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 235000019154 vitamin C Nutrition 0.000 description 4
- 239000011718 vitamin C Substances 0.000 description 4
- 206010006895 Cachexia Diseases 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- 229920001100 Polydextrose Polymers 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 201000011061 large intestine cancer Diseases 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 235000013856 polydextrose Nutrition 0.000 description 3
- 239000001259 polydextrose Substances 0.000 description 3
- 229940035035 polydextrose Drugs 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 229940080237 sodium caseinate Drugs 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000012239 Developmental disease Diseases 0.000 description 2
- 102100025275 Monocarboxylate transporter 3 Human genes 0.000 description 2
- 108091006607 SLC16A8 Proteins 0.000 description 2
- 108010073771 Soybean Proteins Proteins 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 230000005784 autoimmunity Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960004203 carnitine Drugs 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000000242 pagocytic effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 235000019710 soybean protein Nutrition 0.000 description 2
- 235000019605 sweet taste sensations Nutrition 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- SUUWYOYAXFUOLX-ZBRNBAAYSA-N (2s)-2-aminobutanedioic acid;(2s)-2-amino-5-(diaminomethylideneamino)pentanoic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O.OC(=O)[C@@H](N)CCCN=C(N)N SUUWYOYAXFUOLX-ZBRNBAAYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 102100027211 Albumin Human genes 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 206010048832 Colon adenoma Diseases 0.000 description 1
- 241000190633 Cordyceps Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000032456 Hemorrhagic Shock Diseases 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000008934 Muscle Proteins Human genes 0.000 description 1
- 108010074084 Muscle Proteins Proteins 0.000 description 1
- HUSDDORJIJKFPS-FMEGDIDESA-N N[C@@H](CC(=O)O)C(=O)O.C(CC)N[C@@H](CCO)C(=O)O Chemical compound N[C@@H](CC(=O)O)C(=O)O.C(CC)N[C@@H](CCO)C(=O)O HUSDDORJIJKFPS-FMEGDIDESA-N 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 208000033240 Progressive symmetric erythrokeratodermia Diseases 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 206010049771 Shock haemorrhagic Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 206010048259 Zinc deficiency Diseases 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000001612 cachectic effect Effects 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000009229 glucose formation Effects 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 229920000140 heteropolymer Polymers 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100000832 liver cell necrosis Toxicity 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- YRMSKKVGOWJTDQ-UHFFFAOYSA-N methaneselenonic acid Chemical compound C[Se](O)(=O)=O YRMSKKVGOWJTDQ-UHFFFAOYSA-N 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000021062 nutrient metabolism Nutrition 0.000 description 1
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 229940098458 powder spray Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 230000004844 protein turnover Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 201000003780 rectum adenoma Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000004260 weight control Methods 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/723—Xanthans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Pediatric Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a kind of many polymerizers of high energy type enteral nutrition, every 100g gross energy is 450 500kJ, and energy proportioning is: protein 16% 20%, fat 35% 50%, carbohydrate 40% 50%.The present invention has higher fatty acid, the feature of high-energy, low-carb, full nutrition, more conforms to the modern medicine nutrition treatment guide about malignant tumor, has obvious antitumor action, can improve the nutriture of tumor patient.
Description
Technical field
The present invention relates to alimentation composition, particularly to the many polymerizers of high energy type enteral nutrition.
Background technology
The present invention relates to nutritional formulation arts, along with environment, lifestyle change, tumor incidence increases the most year by year.Especially
It is that malignant tumor has become the major disease threatening China resident existence with social development.Malignant tumor patient energy, carbon water
Compound, fat and protein all have and change significantly, energy expenditure increase and inefficient Energy harvesting is considered
Being the underfed reason of tumor mice, the Developmental and Metabolic Disorder of three big heat energy nutrients, the most prominent is abnormal carbohydrate metabolism, main
Lactic acid glucose to be shown as circulation increases, although glucose utilization accelerates, but body is poor to the utilization rate of glucose.
Carcinous dyscrasia is the complicated syndrome that cancer patient exists, and Clinical Manifestations is under chronic, Progressive symmetric erythrokeratodermia body weight
Fall, patient is often accompanied by anorexia, satiety and the performance such as weak.Carcinous dyscrasia patient is insensitive to nutrition treatment or only part
Sensitivity, declines the sensitivity of Radiotherapy chemotherapy, and tolerance reduces, short survival.Cachexia is to cause cancer patient body constitution weak
A key factor with high case fatality rate.Extremely, glyconeogenesis phenomenon is lasting for cachectic patients's sugar, protein, lipid metabolism,
The patient that the cancer patient hepatic glucose synthesis ratio body weight control of body weight consumption is good increases by 40%.Body fat employ increase and
It is the another typical characteristic of cancer cachexia that fat consumption increases, this with Secretion of Catecholamine increase, insulin resistant, tumor or
Other tissue produces and caused by release fat factoring.Steatolysis promotes triacylglycerol fatty acid cycle to strengthen, this circulation
Process consumed energy also causes weight loss.Protein metabolism is abnormal to be increased with breaks down proteins more than closing with total protein turnover rate
One-tenth is characterized.Carcinemia patient increases owing to muscle protein decomposes and albumen synthesis reduces, so that whole body total protein concentration
Reduce.
On domestic market, the enteral nutrition product for tumour patient is few, is especially suitable for dyscrasia patient less.
Home brands product does not has specific aim on formula designs mostly, and formula is originated using casein and/or soybean protein as albumen,
Fatty acid compositions proportioning is single.
Summary of the invention
Because of the too fast growth of tumor, especially after organs shifts, body typically exhibits energy expenditure increase, sugar
Developmental and Metabolic Disorder, lipid mobilization increase and endogenous nitrogen is lost, and the present invention is directed to the metabolic characteristic of tumor organism, it is provided that a kind of high energy
The many polymerizers of type enteral nutrition, improve gross energy, correct metabolism disorder.
It is an object of the invention to be realized by following measures:
A kind of many polymerizers of high energy type enteral nutrition, every 100g gross energy is 450-500kJ, and energy proportioning is: protein
16%-20%, fat 35%-50%, carbohydrate 40%-50%.
The above-mentioned many polymerizers of high energy type enteral nutrition, albumen source is lactalbumin, is allowed to bioavailability the highest.Milk surum
The biological value 104 of albumen, protein efficiency than 3.2, net utilization 92, three groups of data are above lactoprotein (biological value 91, albumen
Matter effect than 3.1, net utilization 82), casein (biological value 77, protein efficiency than 2.5, net utilization 76) and soybean protein
(biological value 74, protein efficiency than 2.1, net utilization 61), is the splendid source that supplements of proteinaceous nutrient.Egg albumen powder of the present invention
Select one or more in concentrated lactoalbumin, sepg whey albumen or lact albumin hydrolysate, profit can be absorbed to greatest extent
With albumen, utilize immunoglobulin and the immunocompetence of lactoferrin and anti-oxidation characteristics in lactalbumin to improve body simultaneously and exempt from
Epidemic disease power.
Cancer cachexia fat employs increase, and the synthesis of the carnitine of body transport fatty acid reduces or excretion increases from urine
Add, cause the carnitine levels in blood plasma and tissue to decline, limit long-chain fatty acid (LCFA) and enter mitochondrial oxidative profit
With.Medium-chain fatty acid (MCT) molecular weight is little, and hydrolysis rate is faster than long-chain fatty acid (LCT), and is not required to camitine transporter, directly
Being decomposed by portal vein to liver and produce energy, it is 4 times of LCT that MCT digests and assimilates speed, and accretion rate is 10 times of LCT.Face
Bed experimental result shows: MCT is significantly less than LCL and glucose in the growth stimulating tumor, and MCT can enrich host's group by preferential
Knit, suppress neoplasm metastasis, be optionally used for treating carcinous dyscrasia.MCT does not produce immunity to the body under stress state to be pressed down
Make use, to inflammatory reaction also without facilitation, be more suitable for the stress state such as operation, wound and use.In view of body to required
The needs of fatty acid, therefore the present invention is by MCT and LCT reasonable employment by a certain percentage ((MCT: LCT is 1: 1).
Fatty powder of the present invention includes medium-chain fatty acid and long-chain fatty acid, and its source includes Semen Maydis oil, soybean oil, Petiolus Trachycarpi
One or more in oil, Oleum Cocois, olive oil, Oleum Camelliae, Oleum Helianthi, fish oil and algae oil.It is combined by multiple fatty acid, adjusts
Whole satisfied fatty acid, monounsaturated fatty acid, the content ratio of polyunsaturated fatty acid are 1: 1: 1, and the ratio of ω-6 and ω-3 is
10: 1～2: 1, preferably 5: 1～2: 1, first-selected 2: 1.Being especially added with the omega-fatty acid of 2-8 part, source includes fish oil, algae oil
In one or both combination after through spraying form.Fructus Maydis oil, Oleum Helianthi lack ω-3-rich in ω-6-PUFA
PUFA.Olive oil, Oleum Camelliae are rich in monounsaturated fatty acid (MUFA).This Fatty acids composition meets taking the photograph of tumour patient fatty acid
Enter.To suppression tumor cell proliferation, promote tumor cell differentiation, improve tumor patient body constitution, improve the survival rate of tumor patient
There is positive role.The dangerous of malignant tumor is occurred substantially to reduce.And the risk of colon cancer morbidity can be reduced.Can substantially slow down
The pathological evolution of patient with breast cancer, alleviates chemotherapeutics side effect and improves survival rate.
The above-mentioned many polymerizers of high energy type enteral nutrition, carbohydrate source is in maltodextrin, and the most only body provides energy
Amount, also organoleptic attribute and stability on product produce impact, embody a concentrated reflection of the DE value outward appearance to finished product of maltodextrin, mouth
Sense, color and luster, the suspending power of solution, viscosity and transparency all have a significant impact.Maltodextrin DE value of the present invention is 10 to 22, excellent
The maltose dextrose selecting DE to be 13-17, sugariness is relatively low, is difficult to make moist, it is difficult to brown stain, modest viscosity, and transparency is preferable.Fructus Hordei Germinatus
When dextrin DE value is lower, though the many polymerizers of nutrition obtained are difficult to make moist, it is difficult to brown stain, suspending power is strong, but product substantially without
Sweet taste, and viscosity is relatively big, and transparency is relatively low.The many polymerizers of nutrition slightly sweet taste when DE value is higher, has certain moisture absorption, thoroughly
Lightness is higher, and viscosity is relatively low, but browning reaction can occur.
Present invention additionally comprises dietary fiber, described dietary fiber includes water soluble dietary fiber and insoluble dietary fiber,
Its amount ratio is 3: 1-1: 3, more preferably 1: 1.Wherein said water soluble dietary fiber derive from inulin, polydextrose,
One or more combinations in oligomeric galactose, oligofructose, polyfructosan, cottonseed sugar, oligomeric xylose, oligomeric isomaltose,
Described insoluble dietary fiber derives from resistant dextrin, soybean fiber, corn bran fiber, beet fiber, Semen Tritici aestivi fiber, Semen Tritici aestivi
One or more combinations kind in bran fiber, Herba avenae fatuae fiber, apple fiber.The present invention occurs under the flora effect of human colon road
Zymolysis, produces and has maintenance Colon mucosa cell for penetrating and update, promoting water and sodium absorption, the short chain of regulating intestinal canal function
Fatty acid, and there is the function reducing enteral nutrition induced diarrhea, improving intestinal.The significance of physiological function of diet fiber with
In dietary fiber, the ratio of water soluble dietary fiber and water insoluble dietary fiber has much relations.
The present invention includes maltodextrin 18-40 part, fatty powder 25-45 part, lactalbumin 18-30 part, dietary fiber 3-7
Part, medium-chain fatty acid 3-5 part, long-chain fatty acid 3-5 part.
Present invention additionally comprises zinc and selenium, its proportioning is zinc 4-6mg/100g, selenium 10-50 μ g/100g.The present invention can strengthen and exempt from
Epidemic disease function, cancer cell specific induction of apoptosis, there is prophylaxis of cancer to have an effect.Selenium Metabolism thing methane-selenonic acid (CH3SeH) can induce cancerous cell
Apoptosis, suppression new vessels is formed, and stops tumor growth or transfer.Clinical evidence display zinc deficiency causes T1, T2 cell function
Disorder, gross tumor volume increases.Selenium Supplement is useful to pulmonary carcinoma and Colon and rectum adenoma and precancerous lesion, and Serum selenium levels is sent out with the esophageal carcinoma
Sick rate is notable negative correlation.
Disease nutrition is combined by the present invention with integration of edible and medicinal herbs theory, is especially added with raw material 1-5 part of integration of edible and medicinal herbs, and it comes
Source includes one or more groups in Radix Ginseng powder, astragalus polysaccharides, Fructus Lycii powder, Cordyceps powder, Cordyceps militaris (L.) Link.sporophore powder, Colla Corii Asini powder
Close.On the one hand on the basis of ensureing body nutritional need, improve patient's autoimmunity, thus reach to alleviate untoward reaction；Separately
On the one hand the active substance utilizing integration of edible and medicinal herbs raw material plays anti-tumor activity, auxiliary suppression tumor growth, reduces the poison of medicine
Side effect, improves tumour patient quality of life.Inflammatory reaction plays a significant role in tumour immunity, and the present invention can change tumor
Microenvironment, reaches suppress the inflammatory reaction of tumor and improve immunity of organisms, and anticancer is bred.The present invention has antioxidation
Damage, regulation immunologic function and effect of inflammatory reaction, can strengthen monocytes/macrophages phagocytic function, stimulates T, bone-marrow-derived lymphocyte
Propagation, strengthens the lymphopoiesis effect of ConA, PHA induction, and many cytokines can be produced impact；And can raise
CD3+, CD4+ cell subsets, lowers CD8+ cell subsets, makes CD4+/CD8+ ratio increase, and improves the concentration of IgA, IgG, the most right
Human body cell and humoral immunoresponse(HI) have potentiation；And tumor necrosis factor α and the level of IL-1 β in liver can be reduced, press down
Transforming growth factor β processed and the level of hydroxyproline, thus alleviate the degree of injury of hepatocellular necrosis and liver；And can improve
Rat traumatic hemorrhagic shock immunosuppressant, tumor necrosis factor (TNF-A) release and the phagocytic activity of macrophage after medication
Significantly improve.
The present invention, on the basis of meeting body ordinary nutritional requirements, also includes arginine≤4 part, glutamine≤4 part,
The most arginic source includes one or more groups in L-arginine, L-arginine hydrochloride, L-arginine-aspartic acid
Closing, the source of glutamine is L-glutaminate.The present invention is made to increase the body immunity to tumor cell to a certain extent.
The present composition adds insoluble dietary fiber and mineral, precipitation easily occurs during reconstituting.For
Improve the structural state of product, improve the suspension stability of product, raw material of the present invention adds xanthan gum the most by weight,
By adjusting the addition of xanthan gum, product of the present invention can be with stable suspersion more than 8 hours after reconstituting.
The above-mentioned many polymerizers of tumorous type enteral nutrition, primary raw material makes by weight: maltodextrin 18-40 part, fat
Powder 25-45 part, lactalbumin powder 18-30 part, dietary fiber 3-7 part, compound vitamin 2-5 part, composite mineral matter 2-5 part, people
Ginseng 0.3 part of powder, Fructus Lycii powder 1.5 parts, 0.5 part of Cordyceps militaris (L.) Link.sporophore powder, astragalus polysaccharides 0.5 part, 1.2 parts of Colla Corii Asini, essence 0.1-0.4
Part.Described compound vitamin is by vitamin A, vitamin D, vitamin E, vitamin K, vitamin B1, vitamin B2, vitamin
B6, vitamin B12, nicotiamide, pantothenic acid, vitamin C, folic acid, biotin, taurine form, described composite mineral matter by sodium,
Potassium, calcium, magnesium, phosphorus, zinc, ferrum, copper, manganese, iodine, selenium, chlorine form.Lactalbumin in the present invention, omega-3 polyunsaturated fatty acids, medicine is eaten
Homology food materials coordinated, improves immunity of organisms, delays and alleviates cancer pathology process.The present invention is directed to market product
Present situation, develops a kind of for the change of tumors of nutrients metabolism substrate and the enteral nutrition heteropolymer of nutrition psychological need, joins
Side originates using lactalbumin as albumen, and fatty acid comprehensively and constitutes proportioning equilibrium, strengthens omega-3 polyunsaturated fatty acids, excavates
Tradition integration of edible and medicinal herbs theory progress adds the tools such as application Radix Ginseng powder, Cordyceps militaris (L.) Link.sporophore powder, Colla Corii Asini powder, Fructus Lycii powder, astragalus polysaccharides
Having the food materials of obvious biologic activities, designed by rational formula, each composition coordinated reaches to correct metabolism disorder, improves
Immunity of organisms, reduces the toxic and side effects of medicine, quality of making the life better, extends malignant tumor patient life cycle.
The above-mentioned many polymerizers of tumorous type enteral nutrition, the nutrition being particularly well-suited to tumour patient chemicotherapy phase tumour patient is propped up
Hold treatment.
Beneficial effect
1. the present invention has higher fatty acid, the feature of high-energy, low-carb, full nutrition, more conforms to modern doctor
Learn the nutrition treatment guide about malignant tumor, there is obvious antitumor action, the nutriture of tumor patient can be improved, I
Result of study show, high energy type enteral nutrition of the present invention was for postoperative 7th day of PATIENTS WITH LARGE BOWEL, and patient's nutritional status is obvious
Improving, plasma A LB, PA, FP level are significantly raised.
2. the present invention be especially added with omega-3 polyunsaturated fatty acids have suppression tumor inflammation, suppress tumor growth, improve
The special efficacy of immunity of organisms, research shows that omega-fatty acid has strong antiinflammatory action, such as the product of suppression PGE2 etc.
Raw, growth of tumour cell can be suppressed, be suitable for tumor patient and use.High energy type enteral nutrition of the present invention is used for PATIENTS WITH LARGE BOWEL art
Latter 7th day, blood samples of patients TNF-α, IL-1 and CRP were significantly lower than preoperative.CRP, IL-1, TNF-α be important inflammatory mediator also
The reflection body inflammatory extent of reaction, clinical research shows that the present invention is by reducing inflammatory factor TNF-α, CRP and IL-1 level control
Make locally and systemically level of inflammation, thus reach antitumor purpose.
3. disease nutrition is combined by the present invention with tradition integration of edible and medicinal herbs theory, is on the one hand ensureing body nutritional need
On the basis of improve patient's autoimmunity, thus reach to alleviate untoward reaction；On the other hand the anti-tumor activity of each component is utilized,
Auxiliary suppression tumor growth, reduces the toxic and side effects of medicine, improves the quality of life of tumour patient.High energy type enteral of the present invention is sought
Supporting for PATIENTS WITH LARGE BOWEL postoperative 7th day, patient's CD4+/CD8+ ratio is apparently higher than preoperative.Tumor immunity mainly shows
Cellular immunization for T cell mediated.T lymphocyte subset group's CD4+, CD8+ and CD4+/CD8+ ratio is reflection immunity of organism
The sensitive indicator of level, CD4+ level raises, and CD4+/CD8+ ratio increases and shows that immunity of organisms strengthens, and shows that power has and carries
The effect of high patients with colorectal cancer operation cellular immune level, the development of containment colorectal cancer is probably effectively by this.
4. the invention provides a kind of enteral nutritional composition particular for tumour patient metabolic characteristic.This formulation product
There is high-energy, higher fatty acid, the feature of high protein, low-carb, it is possible to correct the metabolism disorder occurred；Formula is with breast
Albumin is originated as albumen, plays the biological value of albumen to greatest extent, and formula is especially added with having and lives notable biology
Property food materials etc., formula is focused on fatty acid and comprehensively and is constituted proportioning equilibrium, strengthens omega-3 polyunsaturated fatty acids, by reasonably
Formula designs, and reaches to correct metabolism disorder, improves immunity of organisms, reduces the toxic and side effects of medicine, improves tumour patient life
Quality, extends malignant tumor patient life cycle.
Detailed description of the invention
Below by embodiment, the present invention is specifically described, it is necessary to it is pointed out here that, following example are only
Being used to further illustrate the present invention, it is impossible to be interpreted as limiting the scope of the invention, this skilled person can
The present invention made some nonessential improvement and adjustment according to the invention described above content.
Embodiment 1
A kind of many polymerizers of high energy type enteral nutrition, in terms of parts by weight, composed of the following components:
Fatty powder 30 parts, Oleum Cocois, soybean oil, olive oil, Semen Lini oil after mixing according to the weight ratio of 2: 4: 2: 1,
After mixing with sodium caseinate, obtain emulsion through homogenizing, then emulsion is atomized into drop and is injected to embed containing powder
Being dried in the spray drying device of material, then obtain fatty powder through screening, fat content is 50%；2 parts of fish oil；Algae oil
3 parts.This fat raw material makes satisfied fatty acid, monounsaturated fatty acid, the content ratio of polyunsaturated fatty acid be 1: 1: 1, ω-6
It is 2: 1 with the content ratio of ω-3.Albumen is originated: concentrated lactoalbumin 13.5 parts, 8 parts of sepg whey albumen；Carbohydrate comes
Source: maltodextrin 25 parts；Dietary fiber: inulin 2 parts, polydextrose 1 part, Semen Tritici aestivi fiber 2 parts；(BASF is public for medium-chain fatty acid 5 parts
Department), long-chain fatty acid 5 parts (BASF AG)；Compound vitamin 2 parts of (vitamin A, vitamin D, vitamin E, vitamin K, dimensions
Raw element B1, vitamin B2, vitamin B6, vitamin B12, nicotiamide, pantothenic acid, vitamin C, folic acid, biotin, taurine)；Multiple
Close mineral 2 parts (sodium, potassium, calcium, magnesium, phosphorus, ferrum, copper, manganese, iodine, chlorine)；Zinc 6mg/100g, selenium 50 μ g/100g, Radix Ginseng powder 0.5
Part；Fructus Lycii powder 1.5 parts；0.5 part of Cordyceps militaris (L.) Link.sporophore powder；Xanthan gum 0.3 part；0.2 part of essence.
The many polymerizers of high energy type enteral nutrition of the present invention (seminar) and Nutrison Fibre (matched group) are for PATIENTS WITH LARGE BOWEL art
After, accepting Enteral Nutritional Support 7d during two groups of patient's researchs, two groups of patients serum's ALB, PA, FA levels are apparently higher than hands
Preoperative, and the change of blood glucose, T-CHOL, triglyceride, creatinine, blood urea nitrogen and operation consent comparing difference are without significant, two
Each Indexes Comparison no significant difference (table 1) between group.With matched group and preoperative comparing, postoperative 7th day blood of seminar patient
Liquid TNF-α, IL-1 and CRP level are decreased obviously, and compare with preoperative, and matched group IL-1, TNF-α and CRP level are anticipated without significance
Justice.With matched group and preoperative comparing, postoperative 7th day blood CD4 of seminar+/CD8+Ratio increases；And CD4+、CD8+Change is without aobvious
Work property meaning.During matched group test, immune indexes changes without significant (table 2).Experimental data proves: the present embodiment
The many polymerizers of tumorous type enteral nutrition can improve the malnutrition of patients with colorectal cancer, regulation inflammatory reaction and enhancing human body immunity merit
Can, it is one safely and effectively high energy type enteral nutrition.
Table 1 seminar and matched group enteral nutrition treatment effectiveness comparison
* P ＜ 0.0 is compared with operation consent
2 two groups of Plasma Inflammation Factor Levels In Patients of table and the comparison of immune level level
Above-mentioned experimental data proves: the many polymerizers of tumorous type enteral nutrition of the present embodiment can improve the battalion of patients with colorectal cancer
Support bad, regulation inflammatory reaction and enhancing human body immunity function, be one safely and effectively high energy type enteral nutrition.
Embodiment 2
A kind of many polymerizers of tumorous type enteral nutrition, in terms of parts by weight, composed of the following components:
(Semen Maydis oil, Petiolus Trachycarpi oil, Oleum Cocois, Oleum Camelliae, Oleum Helianthi are according to 2: 4: 2: the weight ratio of 1: 1 is mixed for fatty powder 29 parts
After conjunction, after mixing with sodium caseinate, obtain emulsion through homogenizing, then emulsion is atomized into drop and is injected to containing powder
The spray drying device of embedding material is dried, then obtains fatty powder through screening)；2.5 parts of fish oil；Algae oil 2.5 parts；This
Fat raw material makes satisfied fatty acid, monounsaturated fatty acid, the content ratio of polyunsaturated fatty acid be 1: 1: 1, ω-6 and ω-3
Content ratio be 2: 1.
Concentrated lactoalbumin 20 parts；Lact albumin hydrolysate 3.5 parts；
Maltodextrin 20.4 parts；
Inulin 1 part；Oligomeric xylose 0.5 part；Herba avenae fatuae fiber 1 part；Resistant dextrin 0.5 part；
Zinc 4-6mg/100g, selenium 10-50 μ g/100g；
Medium-chain fatty acid 5 parts (BASF AG), long-chain fatty acid 5 parts (BASF AG)；
Arginine 4 parts, glutamine 4 parts, the most arginic source includes L-arginine, L-arginine hydrochloride, L-essence
Propylhomoserin-aspartic acid mixed in equal amounts, the source of glutamine is L-glutaminate.
Radix Ginseng powder 0.3 part；Fructus Lycii powder 1.5 parts；Astragalus polysaccharides 0.5 part；1.2 parts of Colla Corii Asini powder；Xanthan gum 0.4 part；Essence 0.2
Part.
The many polymerizers of high energy type enteral nutrition of the present invention are used for PATIENTS WITH LARGE BOWEL postoperative 7th day, clinical studies show large intestine
Cancer patient's nutritional status is obviously improved, and plasma A LB, PA, FP level are significantly raised, and blood samples of patients inflammatory mediator TNF-α, IL-1
Substantially reduce with CRP, and blood CD4+/CD8+It is worth significantly raised.The many polymerizers of tumorous type enteral nutrition of the present embodiment can improve
The malnutrition of patients with colorectal cancer, regulation inflammatory reaction and enhancing human body immunity function, be one safely and effectively high energy type intestinal
Interior nutrition.
Embodiment 3
A kind of many polymerizers of tumorous type enteral nutrition, in terms of parts by weight, composed of the following components:
Fatty powder 25 parts is (after being mixed according to the weight ratio of 2: 4: 2: 1 by soybean oil, Petiolus Trachycarpi oil, olive oil, Oleum Camelliae, with cheese
After the mixing of protein acid sodium, obtain emulsion through homogenizing, then emulsion is atomized into drop and is injected to embed material containing powder
Spray drying device in be dried, then obtain fatty powder through screening)；3 parts of fish oil；Algae oil 3 parts；This fat raw material makes to satisfy
Being 1: 1: 1 with fatty acid, monounsaturated fatty acid, the content ratio of polyunsaturated fatty acid, the content ratio of ω-6 and ω-3 is 2:
1。
13.5 parts of sepg whey albumen；Lact albumin hydrolysate 6.5 parts；
Maltodextrin 28.3 parts；
Cottonseed sugar 1 part；Oligomeric isomaltose 1 part；Inulin 1g；Resistant dextrin 2 parts；Apple fiber 1g；
(vitamin A, vitamin D, vitamin E, vitamin K, vitamin B1, vitamin B2, dimension are raw for compound vitamin 2 parts
Element B6, vitamin B12, nicotiamide, pantothenic acid, vitamin C, folic acid, biotin, taurine mixed in equal amounts composition)；Composite mineral matter
2 parts (sodium, potassium, calcium, magnesium, phosphorus, ferrum, copper, manganese, iodine, chlorine mixed in equal amounts form)；
MCT 3 parts；LCT3 part；
Radix Ginseng powder 0.5 part；0.5 part of Cordyceps militaris (L.) Link.sporophore powder；2 parts of Colla Corii Asini powder；Xanthan gum 0.4 part；0.3 part of essence.
The many polymerizers of high energy type enteral nutrition of the present invention are used for PATIENTS WITH LARGE BOWEL postoperative 7th day, clinical studies show large intestine
Cancer patient's nutritional status is obviously improved, and plasma A LB, PA, FP level are significantly raised, and blood samples of patients inflammatory mediator TNF-α, IL-1
Substantially reduce with CRP, and blood CD4+/CD8+It is worth significantly raised.The many polymerizers of tumorous type enteral nutrition of the present embodiment can improve
The malnutrition of patients with colorectal cancer, regulation inflammatory reaction and enhancing human body immunity function, be one safely and effectively high energy type intestinal
Interior nutrition.
Embodiment 4
A kind of many polymerizers of tumorous type enteral nutrition, in terms of parts by weight, composed of the following components:
Fatty powder 33 parts is (by Semen Maydis oil, Petiolus Trachycarpi oil, Oleum Cocois, olive oil, Oleum Helianthi according to 2: 4: 1: the weight of 2: 1
Than mixing after, after mixing with sodium caseinate, obtain emulsion through homogenizing, then emulsion is atomized into drop be injected to containing
The spray drying device of powder embedding material is dried, then obtains fatty powder through screening)；2 parts of fish oil；Algae oil 2 parts；This
Fat raw material makes satisfied fatty acid, monounsaturated fatty acid, the content ratio of polyunsaturated fatty acid be 1: 1: 1, ω-6 and ω-3
Content ratio be 2: 1.
Concentrated lactoalbumin 12.5 parts；6 parts of sepg whey albumen；Lact albumin hydrolysate 4 parts；
Maltodextrin 18.3 parts；
Oligomeric xylose 1 part；Polydextrose 2 parts；Resistant dextrin 2 parts；Soybean fiber 1 part；
(vitamin A, vitamin D, vitamin E, vitamin K, vitamin B1, vitamin B2, dimension are raw for compound vitamin 2 parts
Element B6, vitamin B12, nicotiamide, pantothenic acid, vitamin C, folic acid, biotin, taurine)；Composite mineral matter 2 parts (sodium, potassium,
Calcium, magnesium, phosphorus, ferrum, copper, manganese, iodine, chlorine)；
MCT 3 parts；LCT3 part；
Radix Ginseng powder 0.3 part；0.5 part of Cordyceps militaris (L.) Link.sporophore powder；1.2 parts of Colla Corii Asini powder；Fructus Lycii powder 1.5 parts；Xanthan gum 0.4 part；
0.3 part of essence.
The many polymerizers of high energy type enteral nutrition of the present invention are used for PATIENTS WITH LARGE BOWEL postoperative 7th day, clinical studies show large intestine
Cancer patient's nutritional status is obviously improved, and plasma A LB, PA, FP level are significantly raised, and blood samples of patients inflammatory mediator TNF-α, IL-1
Substantially reduce with CRP, and blood CD4+/CD8+It is worth significantly raised.The many polymerizers of tumorous type enteral nutrition of the present embodiment can improve
The malnutrition of patients with colorectal cancer, regulation inflammatory reaction and enhancing human body immunity function, be one safely and effectively high energy type intestinal
Interior nutrition.
Claims (9)
1. the many polymerizers of tumorous type enteral nutrition, the gross energy of every 100g is 450-500kJ, and energy proportioning is: protein
16%-20%, fat 35%-50%, carbohydrate 40%-50%；Described many polymerizers are made by following weight portion: maltodextrin
18-40 part, fatty powder 25-45 part, lactalbumin powder 18-30 part, dietary fiber 3-7 part, medium-chain fatty acid 3-5 part, long-chain fat
Fat acid 3-5 part, compound vitamin 2-5 part, composite mineral matter 2-5 part, xanthan gum 0.2-0.8 part, Radix Ginseng powder 0.3 part, Fructus Lycii powder
1.5 parts, 0.5 part of Cordyceps militaris (L.) Link.sporophore powder, astragalus polysaccharides 0.5 part, 1.2 parts of Colla Corii Asini.
2. the many polymerizers of tumorous type enteral nutrition as claimed in claim 1, albumen source is lactalbumin, and lactalbumin is selected
One or more in concentrated lactoalbumin, sepg whey albumen or lact albumin hydrolysate.
3. the many polymerizers of tumorous type enteral nutrition as claimed in claim 1, adipose-derived in Semen Maydis oil, soybean oil, Petiolus Trachycarpi oil,
One or more in Oleum Cocois, olive oil, Oleum Camelliae, Oleum Helianthi, fish oil and algae oil, in described fat, satisfied fatty acid, list
Unsaturated fatty acid, polyunsaturated fatty acid content than for 1:1:1, ω-6 the ratio of fatty acid and omega-fatty acid be 10:1
～2:1.
4. the many polymerizers of tumorous type enteral nutrition as claimed in claim 1, carbohydrate source is in maltodextrin；Fructus Hordei Germinatus is stuck with paste
Essence DE value is 10 to 22.
5. the many polymerizers of tumorous type enteral nutrition as claimed in claim 1, described dietary fiber includes water soluble dietary fiber
With insoluble dietary fiber, its amount ratio is 3:1-1:3；Wherein said water soluble dietary fiber derives from inulin, poly-Fructus Vitis viniferae
One or more groups in sugar, oligomeric galactose, oligofructose, polyfructosan, cottonseed sugar, oligomeric xylose, oligomeric isomaltose
Close, described insoluble dietary fiber derive from resistant dextrin, soybean fiber, corn bran fiber, beet fiber, Semen Tritici aestivi fiber,
One or more combinations in Testa Tritici fiber, Herba avenae fatuae fiber, apple fiber.
6. the many polymerizers of tumorous type enteral nutrition as claimed in claim 1, MCT:LCT content ratio is for 1:1.
7. the many polymerizers of tumorous type enteral nutrition as described in claim 1-6 is arbitrary, also include zinc and selenium, and its proportioning is zinc 4-
6mg/100g, selenium 10-50 μ g/100g.
8. the many polymerizers of tumorous type enteral nutrition as described in claim 1-6 is arbitrary, also include arginine≤4 part, glutamy
Amine≤4 part, the most arginic source includes the one in L-arginine, L-arginine hydrochloride, L-argin-ine-aspartic acid
Or multiple combination, the source of glutamine is L-glutaminate.
9. the many polymerizers of tumorous type enteral nutrition as described in claim 1-6 is arbitrary, described compound vitamin by vitamin A,
Vitamin D, vitamin E, vitamin K, vitamin B1, vitamin B2, vitamin B6, vitamin B12, nicotiamide, pantothenic acid, dimension are raw
Element C, folic acid, biotin, taurine composition, described composite mineral matter by sodium, potassium, calcium, magnesium, phosphorus, zinc, ferrum, copper, manganese, iodine, selenium,
Chlorine forms.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410503102.5A CN104207144B (en) | 2014-09-26 | 2014-09-26 | A kind of many polymerizers of high energy type enteral nutrition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410503102.5A CN104207144B (en) | 2014-09-26 | 2014-09-26 | A kind of many polymerizers of high energy type enteral nutrition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104207144A CN104207144A (en) | 2014-12-17 |
| CN104207144B true CN104207144B (en) | 2016-09-14 |
Family
ID=52089355
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410503102.5A Active CN104207144B (en) | 2014-09-26 | 2014-09-26 | A kind of many polymerizers of high energy type enteral nutrition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104207144B (en) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104522665B (en) * | 2014-12-30 | 2017-10-20 | 中恩（天津）医药科技有限公司 | Enteral total nutrient preparation suitable for palliative treatment phase tumor patient and preparation method thereof |
| CN105410932A (en) * | 2015-11-03 | 2016-03-23 | 北京赛升药业股份有限公司 | Tumor immunity type nutritional composition and application thereof |
| CN106880035A (en) * | 2015-12-15 | 2017-06-23 | 范旻 | A kind of total enteral nutritious product of regulating intestinal canal flora imbalance and preparation method thereof |
| CN107440088A (en) * | 2016-06-01 | 2017-12-08 | 华仁药业股份有限公司 | Improve operation, the nutrients and preparation method thereof of chemicotherapy tumor patient immunity |
| CN106036885B (en) * | 2016-06-08 | 2019-05-28 | 裴刚 | Severe and the postoperative Elental and preparation method thereof through nasointestinal tube row |
| CN106579460A (en) * | 2016-12-23 | 2017-04-26 | 上海奥医生物医药科技有限公司 | Special clinical nutrition formula for fracture and preparation method thereof |
| CN106983136A (en) * | 2017-03-29 | 2017-07-28 | 上海奥医生物医药科技有限公司 | A kind of puerperium conditioning tailored version clinical nutrition formula and preparation method thereof |
| CN106942748A (en) * | 2017-03-29 | 2017-07-14 | 上海奥医生物医药科技有限公司 | A kind of female acyesis tailored version clinical nutrition formula and preparation method thereof |
| JP7185626B2 (en) * | 2017-05-26 | 2022-12-07 | 株式会社ヤクルト本社 | Oligosaccharide powder and its production method |
| CN107279993A (en) * | 2017-06-12 | 2017-10-24 | 金梅 | A kind of alimentation composition for promoting patients with gastric cancer early postoperation to recover and its application |
| CN107594540A (en) * | 2017-11-05 | 2018-01-19 | 耿德铨 | Help and breed nutriment composite powder and preparation method thereof |
| CN108703378A (en) * | 2018-05-25 | 2018-10-26 | 上海市浦东医院 | A kind of fro diabetic many polymerizers of the EA |
| CN110170041A (en) * | 2019-07-12 | 2019-08-27 | 深圳福山生物科技有限公司 | It is a kind of for improving the composition of dyscrasia patient symptom |
| CN110771895A (en) * | 2019-11-06 | 2020-02-11 | 上海张新生物医药科技有限公司 | Formula of nutrition support fat component for tumor patients and preparation method of microcapsule powder of nutrition support fat component |
| CN110897153B (en) * | 2019-11-26 | 2022-06-10 | 北京诺葆营养科技有限公司 | Nutritional preparation suitable for patients with kidney disease dialysis |
| CN110892985A (en) * | 2019-11-28 | 2020-03-20 | 北京诺康达医药科技股份有限公司 | Nutritional preparation suitable for perioperative patients |
| CN110839884A (en) * | 2019-12-04 | 2020-02-28 | 上海张新生物医药科技有限公司 | Nutritional composition for improving body inflammatory signs of tumor patients and preparation method thereof |
| CN112841625A (en) * | 2021-01-15 | 2021-05-28 | 首都医科大学附属北京友谊医院 | Nutrient mixture and preparation method thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2081450A1 (en) * | 2006-10-19 | 2009-07-29 | Nestec S.A. | Long-term feed - cancer patient |
| WO2012113415A1 (en) * | 2011-02-24 | 2012-08-30 | N.V. Nutricia | Ketogenic diet composition for the treatment of chemo therapy and/or radiation therapy patients |
| CN102342913A (en) * | 2011-09-06 | 2012-02-08 | 华瑞制药有限公司 | Intra-intestinal nutrient emulsion for tumor patients and preparation method thereof |
| CN103609933A (en) * | 2013-10-31 | 2014-03-05 | 湖北一半天制药有限公司 | Intra-intestinal nutrient emulsion for tumor patients |
-
2014
- 2014-09-26 CN CN201410503102.5A patent/CN104207144B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN104207144A (en) | 2014-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104207144B (en) | A kind of many polymerizers of high energy type enteral nutrition | |
| CN104256595B (en) | A kind of many polymerizers of whole protein type enteral nutrition | |
| Miyata et al. | Randomized study of the clinical effects of ω-3 fatty acid–containing enteral nutrition support during neoadjuvant chemotherapy on chemotherapy-related toxicity in patients with esophageal cancer | |
| CN112089051A (en) | Nutritional composition for improving body inflammatory signs of tumor patients and preparation method thereof | |
| CN104286849A (en) | Diabetes-specific enteral nutrition multi-polymerization agent | |
| CN109846029A (en) | A kind of Elental for cancer patient | |
| JP5462191B2 (en) | Medium chain dicarboxylic acid, its derivatives and metabolic disorders | |
| CN105707878A (en) | Full nutrition formulation food for tumors | |
| CN104146248B (en) | A kind of immunity nourishment composition and application thereof | |
| CN105054025A (en) | Low-fat low-osmosis low-residue type enteral nutritional powder for patients with inflammatory bowel diseases | |
| CN108294306A (en) | A kind of full nutrition special medicine purposes formula food of amino acid pattern | |
| WO2008010472A1 (en) | Total enteral nutrition composition | |
| CN105533696A (en) | Powder type total-nutrient formula food for patients suffering from tumors | |
| CN105410932A (en) | Tumor immunity type nutritional composition and application thereof | |
| CN107440107A (en) | It is a kind of to eat the food formula of special diet containing small peptide for pregnancy reaction crowd | |
| CN101569410A (en) | Special meal nutritional foods used by tumor patients | |
| CN106107463A (en) | Super Quinoa Antifatigue milk tea processing technology | |
| CN109602021A (en) | Nutraceutical containing sialic acid | |
| EP3010357B1 (en) | Administration of a food composition product | |
| CN111436601A (en) | Special clinical nutrition formula for pancreatic cancer and preparation thereof | |
| CN108719977A (en) | A kind of breast cancer nutraceutical and preparation method thereof | |
| CN110150654A (en) | A kind of special medicine purposes formula food for tumor patient | |
| CN108378296A (en) | Peri-operation period nutraceutical | |
| CN101347223B (en) | Cordyceps sinensis potato nutritional vermicelli | |
| CN111802633A (en) | Special clinical nutrition formula for esophageal cancer and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20170512 Address after: 226000 No. 333, Xinxing East Road, Nantong economic and Technological Development Zone, Jiangsu Patentee after: NANTONG LICHENG BIOLOGICAL ENGINEERING Co.,Ltd. Address before: 201, room 4711, No. 200331 traffic road, Shanghai, Putuo District A Patentee before: SHANGHAI RICHEN NUTRITIONAL POLYTRON TECHNOLOGIES INC. |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A kind of high-energy enteral nutrition polymerizer Effective date of registration: 20220831 Granted publication date: 20160914 Pledgee: Industrial Bank Co.,Ltd. Shanghai Putuo sub branch Pledgor: NANTONG LICHENG BIOLOGICAL ENGINEERING Co.,Ltd. Registration number: Y2022310000220 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20231023 Granted publication date: 20160914 Pledgee: Industrial Bank Co.,Ltd. Shanghai Putuo sub branch Pledgor: NANTONG LICHENG BIOLOGICAL ENGINEERING Co.,Ltd.|Nantong Licheng Biotechnology Co.,Ltd. Registration number: Y2022310000220 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A high-energy enteral nutrition polymer Effective date of registration: 20231101 Granted publication date: 20160914 Pledgee: Industrial Bank Co.,Ltd. Shanghai Putuo sub branch Pledgor: NANTONG LICHENG BIOLOGICAL ENGINEERING Co.,Ltd.|Nantong Licheng Biotechnology Co.,Ltd. Registration number: Y2023310000703 |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20240921 Address after: 226000 333 Xinxing East Road, Nantong Development Zone, Nantong City, Jiangsu Province Patentee after: NANTONG LICHENG BIOLOGICAL ENGINEERING Co.,Ltd. Country or region after: China Patentee after: Shanghai Licheng Nutrition Technology Co.,Ltd. Address before: No. 333 Xinxing East Road, Nantong Economic and Technological Development Zone, Jiangsu Province, 226000 Patentee before: NANTONG LICHENG BIOLOGICAL ENGINEERING Co.,Ltd. Country or region before: China |